Amphastar Pharmaceuticals Debt to Equity Ratio 2012-2024 | AMPH
Current and historical debt to equity ratio values for Amphastar Pharmaceuticals (AMPH) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Amphastar Pharmaceuticals debt/equity for the three months ending June 30, 2024 was 0.82.
| Amphastar Pharmaceuticals Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-06-30 |
$0.78B |
$0.71B |
1.09 |
| 2024-03-31 |
$0.90B |
$0.67B |
1.34 |
| 2023-12-31 |
$0.87B |
$0.64B |
1.37 |
| 2023-09-30 |
$0.95B |
$0.60B |
1.60 |
| 2023-06-30 |
$0.79B |
$0.59B |
1.34 |
| 2023-03-31 |
$0.23B |
$0.55B |
0.41 |
| 2022-12-31 |
$0.21B |
$0.53B |
0.40 |
| 2022-09-30 |
$0.22B |
$0.51B |
0.44 |
| 2022-06-30 |
$0.22B |
$0.50B |
0.45 |
| 2022-03-31 |
$0.24B |
$0.48B |
0.49 |
| 2021-12-31 |
$0.23B |
$0.45B |
0.51 |
| 2021-09-30 |
$0.22B |
$0.43B |
0.52 |
| 2021-06-30 |
$0.20B |
$0.47B |
0.43 |
| 2021-03-31 |
$0.20B |
$0.45B |
0.43 |
| 2020-12-31 |
$0.18B |
$0.45B |
0.41 |
| 2020-09-30 |
$0.16B |
$0.45B |
0.36 |
| 2020-06-30 |
$0.16B |
$0.44B |
0.36 |
| 2020-03-31 |
$0.15B |
$0.42B |
0.35 |
| 2019-12-31 |
$0.16B |
$0.43B |
0.37 |
| 2019-09-30 |
$0.15B |
$0.43B |
0.35 |
| 2019-06-30 |
$0.17B |
$0.43B |
0.39 |
| 2019-03-31 |
$0.16B |
$0.38B |
0.43 |
| 2018-12-31 |
$0.15B |
$0.36B |
0.41 |
| 2018-09-30 |
$0.14B |
$0.34B |
0.41 |
| 2018-06-30 |
$0.13B |
$0.32B |
0.41 |
| 2018-03-31 |
$0.12B |
$0.33B |
0.38 |
| 2017-12-31 |
$0.12B |
$0.33B |
0.35 |
| 2017-09-30 |
$0.11B |
$0.33B |
0.32 |
| 2017-06-30 |
$0.11B |
$0.33B |
0.33 |
| 2017-03-31 |
$0.11B |
$0.33B |
0.34 |
| 2016-12-31 |
$0.10B |
$0.33B |
0.30 |
| 2016-09-30 |
$0.10B |
$0.33B |
0.31 |
| 2016-06-30 |
$0.10B |
$0.31B |
0.33 |
| 2016-03-31 |
$0.10B |
$0.30B |
0.33 |
| 2015-12-31 |
$0.10B |
$0.30B |
0.32 |
| 2015-09-30 |
$0.11B |
$0.28B |
0.39 |
| 2015-06-30 |
$0.11B |
$0.29B |
0.40 |
| 2015-03-31 |
$0.12B |
$0.28B |
0.42 |
| 2014-12-31 |
$0.11B |
$0.28B |
0.38 |
| 2014-09-30 |
$0.12B |
$0.28B |
0.42 |
| 2014-06-30 |
$0.11B |
$0.29B |
0.38 |
| 2014-03-31 |
$0.09B |
$0.25B |
0.37 |
| 2013-12-31 |
$0.09B |
$0.25B |
0.35 |
| 2013-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2013-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2013-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2012-12-31 |
$0.08B |
$0.23B |
0.36 |
| 2012-09-30 |
$0.00B |
|
0.00 |
| 2012-06-30 |
$0.00B |
|
0.00 |
| 2012-03-31 |
$0.00B |
|
0.00 |
| 2011-12-31 |
$0.00B |
$0.00B |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$2.469B |
$0.644B |
|
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
|
